Clinical Trial News
FDA Approves Pyzchiva (ustekinumab-ttwe), a Biosimilar to Stelara
FDA approves Sandoz's biosimilar Pyzchiva® (ustekinumab-ttwe), developed by Samsung Bioepis, for all indications of Stelara®, including treating moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Pyzchiva® is set to launch in the US in February 2025, aiming to provide affordable biosimilar alternatives for patients.
FDA Approves Tepylute (thiotepa) Ready-to-Dilute Injectable Formulation to Treat Breast Cancer and Ovarian Cancer
Shorla Oncology's Tepylute, a liquid form of thiotepa, simplifies oncology drug use, reducing medical personnel exposure to hazardous drugs. It's Shorla's third FDA-approved drug and their first in-house developed NDA, aiming to address unmet needs in cancer treatment.
Epkinly (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
U.S. FDA approves Epkinly (epcoritamab-bysp) for relapsed or refractory follicular lymphoma after two or more lines of therapy, making it the first subcutaneous T-cell engaging bispecific antibody for this patient population. Approval based on response rate; continued approval contingent on clinical benefit verification in confirmatory trials.
Related Clinical Trials:
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
FDA issues Complete Response Letter for Daiichi Sankyo and Merck's patritumab deruxtecan BLA due to inspection findings at a third-party manufacturer, without issues identified with efficacy or safety data. Patritumab deruxtecan is a potential first-in-class HER3-directed ADC, jointly developed by Daiichi Sankyo and Merck, aiming to treat EGFR-mutated NSCLC patients previously treated with two or more systemic therapies.
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
AbbVie received a Complete Response Letter from the FDA for ABBV-951, a treatment for motor fluctuations in advanced Parkinson's disease, due to observations during inspection of a third-party manufacturer. The CRL does not raise issues on safety, efficacy, or labeling of ABBV-951.
Ionis Announces Olezarsen New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed
Ionis Pharmaceuticals' olezarsen NDA accepted for Priority Review by FDA for FCS treatment, with action date set for December 19, 2024. Phase 3 sHTG program enrollment completed. Olezarsen targets apoC-III to lower triglyceride levels, reducing acute pancreatitis risk in FCS and sHTG patients.
KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema
KalVista submits NDA to FDA for sebetralstat, an oral on-demand treatment for HAE, based on phase 3 trial results showing faster symptom relief than placebo. The drug is well-tolerated with no treatment-related SAEs. FDA has a 60-day review period, with potential approval leading to the first oral on-demand HAE therapy.
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Iterum Therapeutics' NDA resubmission for oral sulopenem to treat uncomplicated urinary tract infections in adult women is accepted by the FDA, with a PDUFA action date of October 25, 2024.
U.S. FDA Acknowledges Astellas' Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date
Astellas' resubmission of the Biologics License Application (BLA) for zolbetuximab, a CLDN18.2-targeted monoclonal antibody for first-line treatment of HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, has been acknowledged by the U.S. FDA, setting a new action date of November 9, 2024.
Related Clinical Trials:
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for Cardamyst
Milestone Pharmaceuticals announced the FDA accepted their New Drug Application for Cardamyst (etripamil) nasal spray, intended for paroxysmal supraventricular tachycardia (PSVT) management. The PDUFA target date is set for 10 months after the acceptance date. Cardamyst aims to provide a new, convenient treatment option for PSVT patients, potentially allowing self-management without medical supervision.